VALANX Biotech develops a novel, site-specific protein conjugation technology. It is cost efficient, IP-protected and serves as a great starting point for your bioconjugate development process. Our technology gives you a chemically defined conjugation product therefore greatly easing clinical development.
Opernring 16/1
8010 Graz
Styria
Contact: Michael Lukesch (CEO)
Telephone: +43 (650) 822-1080
Email: lukesch@valanx.bio.com
Website